+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05963867

Open-label Trial Investigating 89ZrZr-BI 764532 Imaging and Tumor Uptake in Adults with Small Cell Lung or Neuroendocrine Cancer

Led by Boehringer Ingelheim · Updated on 2026-10-14

12

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how the medicine BI 764532 is distributed in the body and taken up by tumors in adults with small cell lung cancer or other neuroendocrine cancers. This study focuses on people with advanced cancer for whom previous treatments have not worked or no standard treatment options exist. It aims to better understand the behavior of BI 764532 in tumors using imaging technology. Participants receive BI 764532 as treatment beginning at study start. During the first weeks, doctors use an imaging method to observe how the medicine is absorbed by tumors. If participants benefit and tolerate the treatment well, they may continue receiving BI 764532 for up to the total study duration. The number of visits depends on each participants response and tolerance. Throughout the study, participants attend regular visits where doctors monitor their general health, record any side effects, and perform assessments. The main measurement is the change in BI 764532 levels in tumors compared to blood plasma over about 35 days. The study lasts until January 15, 2027, with ongoing evaluations to understand the medicines effects and safety.

CONDITIONS

Brief Title

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here